Low dose naltrexone in the treatment of dissociative symptoms

被引:6
作者
Pape, W. [1 ]
Woeller, W. [1 ]
机构
[1] Krankenhaus Psychosomat Med & Psychotherapie, Rhein Klin, D-53604 Bad Honnef, Germany
来源
NERVENARZT | 2015年 / 86卷 / 03期
关键词
Dissociation; Endogenous opiates; Naltrexone; Low dose medication; Complex posttraumatic stress disorder; BORDERLINE PERSONALITY-DISORDER; POSTTRAUMATIC-STRESS-DISORDER; TRIAL;
D O I
10.1007/s00115-014-4015-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Following the hypothesis that blocking opioid receptors leads to a decline in opiate-modulated dissociative phenomena, experiences with naltrexone as medication for dissociative symptoms have been gained since 1999 (mainly in doses of 25-100 mg/day). In this study patients with severe trauma-related and dissociative disorders were treated with naltrexone in doses of 2-6 mg/day (0.06 mg/kg body weight). The low dose treatment with naltrexone proved to be effective whereby 11 out of 15 patients reported immediate positive effects and 7 described a lasting helpful effect. The majority of patients who felt positive effects reported a clearer perception of both their surroundings and their inner life. Assessment of reality and dealing with it improved as did the perception of their own body and affects as well as self-regulation. The treatment was very low in side effects. Treatment with low-dose naltrexone may be a helpful element in the treatment of patients with complex posttraumatic stress disorder. However, it has to be realized that the decrease of dissociation may lead patients to a not yet resolvable challenge, in as much as dissociation had previously been a necessary mechanism of self-protection.
引用
收藏
页码:346 / 351
页数:6
相关论文
共 15 条
  • [1] Borderline Personality Disorder: A Dysregulation of the Endogenous Opioid System?
    Bandelow, Borwin
    Schmahl, Christian
    Falkai, Peter
    Wedekind, Dirk
    [J]. PSYCHOLOGICAL REVIEW, 2010, 117 (02) : 623 - 636
  • [2] Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder:: An open-label trial
    Bohus, MJ
    Landwehrmeyer, GB
    Stiglmayr, CE
    Limberger, MF
    Böhme, R
    Schmahl, CG
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (09) : 598 - 603
  • [3] Bolm T, 2002, THESIS U HAMBURG
  • [4] Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
    Bowirrat, Abdalla
    Chen, Thomas J. H.
    Blum, Kenneth
    Madigan, Margaret
    Bailey, John A.
    Chen, Amanda Lih Chuan
    Downs, B. William
    Braverman, Eric R.
    Radi, Shahien
    Waite, Roger L.
    Kerner, Mallory
    Giordano, John
    Morse, Siohban
    Oscar-Berman, Marlene
    Gold, Mark
    [J]. CURRENT NEUROPHARMACOLOGY, 2010, 8 (04) : 335 - 358
  • [5] A Naturalistic Study of Dissociative Identity Disorder and Dissociative Disorder Not Otherwise Specified Patients Treated by Community Clinicians
    Brand, Bethany
    Classen, Catherine
    Lanins, Ruth
    Loewenstein, Richard
    McNary, Scott
    Pain, Claire
    Putnam, Frank
    [J]. PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY, 2009, 1 (02) : 153 - 171
  • [6] Freyberger HJ, 1998, PSYCHOTHER PSYCH MED, V48, P223
  • [7] Are there two qualitatively distinct forms of dissociation? A review and some clinical implications
    Holmes, EA
    Brown, RJ
    Mansell, W
    Fearon, RP
    Hunter, ECM
    Frasquilho, F
    Oakley, DA
    [J]. CLINICAL PSYCHOLOGY REVIEW, 2005, 25 (01) : 1 - 23
  • [8] Lanius U, 2014, EMBODIED SELF NEUROL
  • [9] Lanius U. F, 2005, EMDR SOLUTIONS PATHW, P121
  • [10] Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study
    Lubin, G
    Weizman, A
    Shmushkevitz, M
    Valevski, A
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2002, 17 (04) : 181 - 185